Finnish well being know-how pioneer CurifyLabs, has acquired vital mental property (IP) from Mehta Heino Industries Oy, a Finnish 3D printing {hardware} growth firm. The acquisition marks a pivotal second in CurifyLabs’ functionality to supply unparalleled 3D printing options for producing customized medicines within the pharma trade.
“The acquisition of Mehta Heino’s IP and different belongings is a game-changer for us. Their modern method to 3D printing know-how completely aligns with our imaginative and prescient enabling wider adoption of customized therapies. This acquisition isn’t merely about rising our portfolio; it’s about main the trade into a brand new period,” mentioned Charlotta Topelius, Co-founder and CEO of CurifyLabs.
Along with the IP acquisition, Petri Heino, CTO of Mehta Heino, has joined CurifyLabs as Lead {Hardware} Engineer. “CurifyLabs presents a rare alternative to push the boundaries of what’s potential in 3D printing and superior robotics in healthcare. Me and my Co-founder Santosh Mehta spent eight years creating our know-how and we’re thrilled to see our IP contribute to groundbreaking developments for the advantage of weak affected person populations that want customized therapies,” mentioned Petri Heino.
CurifyLabs’ Pharma Equipment resolution, which mixes modern printable Pharma Inks with 3D printing know-how and high quality management, supplies an automatic resolution for producing customized medication in hospitals and compounding pharmacies. The answer eliminates the handbook course of and makes compounding extra accessible, cost-effective, secure, and scalable.
“For pharmacies, pace, seamless workflows, and regulatory compliance are important. We allow this with our distinctive customized medication manufacturing resolution. With Mehta Heino’s IP, we’re taking our dedication to efficient options to the subsequent degree. Our mixed experience will end in extra environment friendly manufacturing options, facilitating the broader adoption of customized medication and enhanced look after sufferers with particular person wants,” mentioned Niklas Sandler, Co-founder and CTO at CurifyLabs.
“We should pay particular consideration to pediatric populations the place customized medicines are essential. The IP acquisition and including Petri to our staff improve our capability to just do that,” mentioned Charlotta Topelius.
